Related by context. All words. (Click for frequent words.) 69 Phase Ib clinical 67 Phase IIb III 67 phase IIa clinical 67 CA9 SCAN 67 phase IIb clinical 66 Phase 1a clinical 65 multicenter Phase II 65 confirmatory clinical 65 CBLC# 65 Phase IIB 65 Phase Ib II 64 phase IIa 64 Phase #b/#a clinical 64 Phase Ib study 64 phase Ib clinical 63 lorvotuzumab mertansine 63 Phase IIIb clinical 63 multicenter clinical 63 Phase 2a clinical 63 NP2 Enkephalin 63 Phase IIb clinical trials 63 Phase 1b clinical 62 Phase IIa clinical 62 BRIM3 62 Phase #b/#a 62 placebo controlled clinical 62 lomitapide 62 cannabinor 62 Phase 1b trial 62 phase IIb study 62 confirmatory Phase III 62 Phase IIb clinical 62 neratinib 62 pivotal bioequivalence 62 Phase III registrational 62 double blinded randomized 62 phase IIIb 61 phase IIb 61 alvespimycin 61 Phase Ib IIa 61 randomized Phase IIb 61 Oral NKTR 61 pharmacodynamic markers 61 IIa trial 61 pharmacokinetic PK study 61 vidofludimus 61 vivo potency 61 midstage trials 61 phase IIb trial 61 ganaxolone 61 dose escalation Phase 61 thorough QT 61 DXL# 61 Phase IIB clinical 61 preclinical efficacy 61 tolerability pharmacokinetics 61 Phase III confirmatory 61 mertansine 60 Androxal TM 60 Phase 2b clinical trials 60 preclinical pharmacokinetic 60 IIa clinical 60 CRLX# 60 Azedra 60 preclinically 60 HGS# 60 phase 2a 60 GRNVAC1 60 novel oral anticoagulant 60 huC# DM4 60 huN# DM1 60 AQ4N 60 BNC# 60 FOLOTYN ® 60 CEQ# 60 Phase IIb trials 60 Phase lll 60 trastuzumab emtansine T DM1 60 ZYBRESTAT fosbretabulin 60 CG# [003] 60 fosbretabulin 60 Trofex 60 multicenter Phase 60 JAK inhibitor 60 phase Ib 60 randomized controlled Phase 60 PDE4 inhibitor 60 clinical pharmacology studies 60 dose escalation clinical 60 Phase 1a 60 IIa trials 60 Lisofylline LSF 60 Phase #/#a 60 GRAVITAS trial 60 placebo controlled Phase III 60 Phase IIa trials 60 Spiegelmer ® 60 ONCONASE R 60 MEK inhibitor RDEA# 60 bicifadine 60 RH1 60 CHAMPION PCI 60 trodusquemine 59 BrachySil TM 59 GLP toxicology studies 59 hypoxia activated prodrug 59 pharmacodynamic PD 59 Pimavanserin 59 nonclinical studies 59 NOX E# 59 Phase III psoriasis 59 multicenter randomized placebo controlled 59 Plicera 59 SUCCEED trial 59 IMA# 59 subcutaneous PRO 59 tanespimycin 59 pharmacodynamic effects 59 multicentre randomized 59 BLA filing 59 Phase IIIb study 59 vivo preclinical 59 mg/m2 cohort 59 dose escalation trial 59 TLK# 59 randomized Phase 2b 59 R roscovitine 59 Phase IIa trial 59 pharmacokinetic PK profile 59 Phase 2b study 59 Phase 2b clinical 59 TransVax tm 59 pharmacodynamic properties 59 Cloretazine ® 59 PRIMO CABG 59 ORE# 59 ABSORB clinical 59 Phase IIA 59 Phase Ib 59 farletuzumab 59 clinicaltrials 59 trial evaluating PRX# 59 TG# [003] 59 Anavex #-# 59 vascular disrupting agent 59 rALLy clinical trial 59 safety tolerability pharmacokinetic 59 generation URAT1 inhibitor 59 ruxolitinib 59 ASSERT trial 59 MEND CABG 59 rotary VAD 59 CLORETAZINE TM VNP#M 59 Phase 2a trial 59 Archexin 59 Fx #A 59 Lu AA# 59 ulimorelin 59 Prodarsan 59 investigational protease inhibitor 59 multicenter randomized controlled 59 pharmacokinetic pharmacodynamic 58 inhaled AAT 58 pharmacokinetics PK 58 CB2 selective receptor agonist 58 BRIM2 58 axitinib 58 Phase 2b trial 58 TASKi3 58 Prodarsan ® 58 PSN# [002] 58 Pharmacokinetic studies 58 EP #R 58 pharmacodynamic profile 58 registrational Phase 58 volociximab 58 Xanafide 58 tremelimumab 58 Zoraxel 58 telomerase inhibitor drug 58 PRESEPT 58 depsipeptide 58 PSMA ADC 58 CARE HF 58 SCENESSE ® 58 INCB# [001] 58 Liprostin 58 registrational 58 confirmatory Phase 3 58 Clinical Antipsychotic Trials 58 pharmacokinetic parameters 58 optimal dosing regimens 58 investigational pan BCR 58 crizotinib PF # 58 bardoxolone 58 urocortin 2 58 initiate Phase 1b 58 ongoing Phase 1b 58 afamelanotide 58 Phase III randomized controlled 58 SAR# [004] 58 forodesine 58 OHR/AVR# 58 Aurexis 58 CRMD# 58 Phase Ia 58 pertuzumab 58 randomized blinded 58 Posiphen 58 PF # [002] 58 randomized Phase III 58 tramiprosate Alzhemed TM 58 Nasdaq ONXX today 58 GLPG# 58 desvenlafaxine succinate 58 ToGA 58 Phase #b/#a trial 58 ARIKACE ™ 58 oral prodrug 58 tiapamil 58 omacetaxine mepesuccinate 58 ANAVEX #-# [001] 58 oral deforolimus 58 Curaxin 58 Vaxfectin TM 58 AVERROES 58 phase IIb III 58 orally dosed 58 DAC HYP 58 Elocalcitol 58 multicenter randomized clinical 57 Hedgehog antagonist 57 TBC M4 57 GALNS 57 olaparib 57 riociguat 57 p# inhibitor 57 Zybrestat 57 IIa clinical trial 57 Quinamed 57 optimal dosing 57 non nucleoside HCV 57 NV1FGF 57 immunotherapeutic vaccine 57 Anturol TM 57 initiate Phase 2b 57 pharmacokinetic PK 57 eTag assays 57 triphendiol 57 APEX PD 57 deforolimus 57 OvaRex ® MAb 57 Phase 2b kidney transplant 57 subcutaneous formulation 57 PEGPH# 57 dose cohort 57 R#/MEM # 57 AZILECT ® 57 EndoTAG TM -1 57 dose escalation phase 57 Curaxin CBLC# 57 Afatinib 57 StemEx 57 EXPLORE Xa 57 rALLy trial 57 ADVANCE PD 57 prospective multicenter study 57 GAP #B# 57 RhuDex 57 ATL# [001] 57 teriflunomide 57 Onconase 57 Panzem R NCD 57 NO# [002] 57 EGS# 57 STRIDE PD 57 PrevOnco 57 TACI Ig 57 candidate CRLX# 57 Solorel TM 57 Capesaris 57 XL# SAR# 57 PDE# inhibitors 57 SNT MC# 57 RGB # 57 Phase Ib clinical trials 57 YONDELIS 57 Phase 2a 57 randomized multicenter Phase III 57 Cloretazine 57 VITAL Trial 57 Sym# 57 Annamycin 57 PrevOnco ™ 57 StemEx R 57 LungExpress Dx TM 57 genomic biomarker 57 AERAS-#/Crucell Ad# 57 unblinding 57 PANVAC VF 57 Exelixis compounds 57 tubulin inhibitor 57 placebo controlled randomized 57 ospemifene 57 PEG SN# 57 Phase III clinical 57 randomized controlled multicenter 57 Proellex TM 57 HuMax EGFr 57 ADMIRE HF 57 IND submission 57 TRIST study 57 ANCHOR trial 57 Phase III multicenter 57 Octreolin 57 generation purine nucleoside 57 MGd 57 oral methylnaltrexone 57 durable pain palliation 57 Poly ICLC 57 novel VDA molecule 57 Phase III 57 tolevamer 57 Phase IIb 57 Ophena 57 bioFILM PA TM 57 CR# vcMMAE 57 PROSTVAC TM 57 Laquinimod 57 Tarvacin TM 57 molecular biomarker 57 orally inhaled migraine 57 favorable pharmacokinetic profile 57 Intervention Effectiveness 57 hepatitis B vaccine Heplisav 57 randomized controlled clinical 57 Allovectin 7 R 57 Surfaxin LS 57 Prostate AdenoCarcinoma Treatment 57 tumorigenicity 57 budesonide foam 57 AKT inhibitor 57 ProSavin 57 Lpathomab 57 anticancer compound 57 velafermin 57 Phase 1b dose escalation 57 PI3 kinase inhibitors 57 PEARL SC 57 Orazol 57 CVac 57 EMPHASIS HF trial 57 oral salmon calcitonin 57 TRO# 57 RhuDex ® 57 CURRENT OASIS 7 57 oral picoplatin 57 evaluating tivozanib 56 BST CarGel R 56 Hsp# Inhibitor 56 Asentar 56 elotuzumab 56 PFO migraine 56 Phase 2a clinical trials 56 OvaRex MAb 56 NADiA ProsVue 56 lumiliximab 56 mTOR inhibition 56 QLT Plug Delivery 56 Perceiva 56 Phase 2b randomized 56 arzoxifene 56 epigenetic therapies 56 lucinactant 56 safety tolerability pharmacokinetics 56 MEND CABG II 56 assessing T DM1 56 Pertuzumab 56 Zenvia ™ 56 Phase II 56 OvPlex 56 vorinostat 56 GAMMAGARD 56 trastuzumab DM1 T DM1 56 Dacogen injection 56 NEUVENGE 56 ENRICH trial 56 NABTT 56 XmAb# 56 eniluracil 56 retaspimycin 56 NeuVax 56 LUX Lung 56 concurrent chemoradiation 56 BEZ# 56 AERx iDMS 56 indibulin 56 histamine dihydrochloride 56 cortical stimulation 56 midstage studies 56 plasma pharmacokinetics 56 PXD# 56 Multimeric 56 PET tracers 56 TRX1 56 registrational trial 56 relapsed MCL 56 biostatistical analysis 56 eprotirome 56 Phase 2b 56 Evoltra TM 56 Vitaxin 56 Safinamide 56 OncoVEX GM CSF 56 Randomized controlled 56 ularitide 56 OvaRex R 56 Troxatyl 56 Ketotransdel 56 IMC A# 56 PLX cells 56 Tykerb lapatinib 56 Phase 2b monotherapy 56 ocular formulation 56 HGS ETR2 56 multiple ascending dose 56 CCR5 inhibitor 56 Phase IIa 56 rALLy 56 GATTEX ® 56 TLR antagonists 56 TBC# 56 Fibrillex TM 56 Prosaptide 56 IMC #B 56 NEUGENE R 56 selective androgen receptor modulator 56 OncoVex 56 OMAPRO 56 haematological cancers 56 Exherin TM 56 antiangiogenic agent 56 including eniluracil ADH 56 Phase III placebo controlled 56 radiation sensitizer 56 TASKi2 56 castrate resistant prostate cancer 56 randomized multicenter trial 56 Clonicel 56 cMET 56 TEMSO 56 formal pharmacokinetic PK 56 ritonavir boosted danoprevir 56 USL# 56 viral kinetics 56 multicenter trials 56 radiation dosimetry 56 enzastaurin 56 IL# PE#QQR 56 Oncotype DX colon cancer 56 PEP# [003] 56 Aplidin 56 Vacc 4x 56 placebo controlled multicenter 56 lintuzumab 56 multiple myeloma MM 56 GOUT 56 Novolimus 56 GSK# [002] 56 oral ridaforolimus 56 prospective randomized controlled 56 SYMMETRY trial 56 ACCLAIM II 56 OMP #M# 56 HGS ETR1 56 entinostat 56 antiviral efficacy 56 acyclovir Lauriad R 56 ELACYT 56 AeroLEF TM 56 solithromycin 56 DEEP AF 56 DPX Survivac 56 Ceflatonin 56 Panzem 56 EDEMA3 56 bioequivalency 56 PD LID 56 Telintra 56 unblind 56 GLYX 56 investigational humanized monoclonal antibody 56 Phase 1b 56 trastuzumab DM1 56 prokinetic agent 56 LCP AtorFen 56 dirucotide MBP# 56 SCIB1 56 BioSTAR R 56 e2 Collector 56 REVIVE Diabetes 56 Memryte 56 pharmacodynamics PD 56 Urocidin 56 Thorough QT 56 MAGE A3 ASCI 56 motesanib 56 VNP#M 56 APTIVUS 56 unique alkylating agent 56 Traficet EN 56 pediatric malignancies 56 intravenous methylnaltrexone 56 Cannabinor 56 SCH # 55 rBChE 55 ResponseDX Lung TM 55 ASONEP 55 cathepsin K inhibitor 55 midstage clinical 55 NADiA 55 XmAb 55 Zemplar Capsules 55 Phase IIIb 55 Phase 1b clinical trials 55 elacytarabine 55 galiximab 55 Tyrima 55 vitro ADME 55 PHX# 55 immunotherapeutic approaches 55 Harry Palmin President 55 Solorel 55 OncoGel 55 fidaxomicin Phase 3 55 IMPACT DCM 55 ADAGIO study 55 NCCTG 55 AMPK activators 55 pharmacokinetic equivalence 55 sunitinib malate 55 tramiprosate 55 non nucleoside 55 SUTENT ® 55 peptide conjugated 55 BEMA Granisetron 55 IND enabling 55 reslizumab 55 paclitaxel poliglumex 55 OvaRex 55 ZOLINZA 55 Phase III HEAT 55 Bayer HealthCare Onyx Pharmaceuticals 55 Corlux 55 novel histone deacetylase 55 HQK 55 randomized multicentre 55 multicenter Phase III 55 cangrelor 55 HuCAL antibodies 55 rindopepimut 55 INS# [001] 55 Vectibix panitumumab 55 Virulizin ® 55 AIM HIGH 55 PS# DARA 55 targeted radiotherapeutic 55 CA4P 55 kinase inhibition 55 MCSP respectively 55 delafloxacin 55 double blinded placebo 55 novel therapeutic antibodies 55 Pharmacodynamic 55 Factor VIIa 55 MIST II 55 dimebon latrepirdine 55 aerosolized KL4 surfactant 55 CTAP# Capsules 55 ENMD # 55 wilate ® 55 PROCHYMAL 55 Amoxicillin PULSYS Phase III 55 ATL# [002] 55 Tasimelteon 55 Panzem ® 55 Azedra TM 55 PreCISe 55 ataluren 55 masitinib 55 TH# [003] 55 Enzastaurin 55 EOquin TM 55 GetGoal Phase III 55 Valtropin 55 evaluating REVLIMID 55 endothelin antagonists 55 orBec 55 Cytolin R 55 Personalized Immunotherapy 55 PERSEUS 55 CDP# 55 Bezielle 55 blinded randomized placebo controlled 55 generation NNRTI 55 adrenergic regulation 55 pharmacogenetic testing 55 SPIRIT FIRST 55 nanopharmaceutical 55 pain palliation 55 dexanabinol 55 CD# CEA 55 dosing cohort 55 pharmacokinetic properties 55 TMC# C# 55 Maximum Tolerated Dose MTD 55 davunetide intranasal AL 55 next generation URAT1 55 Phase III randomized 55 TOLAMBA 55 Multiple Ascending Dose 55 DACH platinum 55 GLP toxicology 55 ongoing Phase IIIb 55 initiate Phase IIa 55 MVA MUC1 IL2 55 LungAlert TM 55 OVATURE 55 ACCEDE 55 ritonavir boosting 55 DEB# 55 KRN# 55 cystinosis patients 55 VIR# 55 tezampanel NGX# 55 #I TM# 55 gepirone ER 55 thymalfasin 55 Angiocept 55 Cloretazine R VNP#M 55 #D#C# 55 OnDose TM 55 relapsed MM 55 Forodesine HCl 55 ThermoDox R 55 CYT# 55 ChronVac C ® 55 Symadex 55 oral PTH 55 CaPre TM 55 incyclinide 55 RSD# oral 55 multicentre randomized controlled 55 relapsing multiple sclerosis 55 chemopreventive agent 55 teplizumab 55 Lovaxin C 55 pomalidomide 55 ILLUMINATE 55 DSMB recommended 55 CRD5 55 CUSTOM III 55 Preclinical studies 55 vivo validation 55 isoform selective 55 Mipomersen 55 JP-#/fipamezole 55 Preclinical studies suggest 55 Medidur TM FA 55 histone deacetylase HDAC inhibitor 55 mapatumumab 55 bevirimat Study 55 bardoxolone methyl 55 intranasal formulation 55 SEPET TM 55 Prestara TM 55 Diamyd R 55 octreotide implant 55 selective modulator 55 rxRNA 55 RE SURGE 55 NS5A inhibitor 55 Aplidin R 55 Canvaxin TM 55 IMPACT DCM clinical 55 RLY# 55 European Sepsis Trial 55 BrachySil ™ 55 RG# [001] 54 anti fibrotic 54 pharmacodynamic endpoints 54 dirucotide 54 refractory colorectal cancer 54 afatinib 54 AE# vaccine 54 efficacy endpoint 54 cardiac repolarization 54 OLYMPIA registry 54 Tocosol Paclitaxel 54 histone deacetylase inhibitor 54 preclinical toxicology 54 pharmacokinetics pharmacodynamics 54 relapsed ALL 54 Heplisav 54 recurrent glioblastoma multiforme 54 prospective multicenter 54 MYTHOS trial 54 cilengitide 54 DAVANAT 54 brivaracetam 54 HDL Selective Delipidation 54 HIF PH inhibitors 54 Canvaxin 54 AVADO 54 genomic biomarkers 54 Diamyd r vaccine 54 CMV vaccine 54 confirmatory pivotal 54 TELCYTA 54 pharmacokinetic pharmacodynamic PK PD 54 Daclizumab 54 ticagrelor Brilinta 54 vaginally administered lidocaine 54 blinded randomized 54 pharmacokinetic characteristics 54 plasma kallikrein inhibitor 54 APTIMA HPV 54 HepeX B TM 54 RhuDex R 54 Oglemilast 54 rFIXFc 54 Prestara 54 IRX 2 54 Guanilib 54 QTinno TM 54 oral rivaroxaban 54 multicenter phase 54 Alequel 54 Vaxfectin R formulated 54 PhG alpha 1 54 Serada 54 JAK2 inhibitors 54 presymptomatic 54 Kamada AAT 54 safinamide 54 Dr. Gabriel Lasala 54 TransMID 54 satraplatin Phase 54 Tarceva TM 54 CCX# 54 PROVENGE sipuleucel T 54 GeoVax vaccine 54 Phase #/#a trial 54 Phase III pivotal 54 PRT# 54 efficacy tolerability 54 Eniluracil 54 NASDAQ CXSP announced 54 lead Aganocide compound 54 Phase IIb trial 54 GV# [001] 54 randomized discontinuation 54 LEVADEX ™ 54 JAK2 inhibitor 54 Tavocept 54 cytokine refractory 54 Active Ulcerative Colitis 54 PROVENGE ® 54 Bicifadine 54 PEG IFN 54 BETAS 54 CytoFabTM 54 gemcitabine Gemzar ® 54 ibudilast 54 AVN# Phase 54 refractory prostate cancer 54 DermaVir Patch 54 velafermin belinostat 54 prospective multicentre 54 Pharmacokinetics PK 54 genotoxicity 54 ThermoDox ® 54 diagnostic biomarker 54 BRAF inhibitors 54 QTinno 54 PEG PAL 54 Pre RELAX AHF 54 cariprazine 54 Valdoxan 54 aurora kinase 54 MOZOBIL 54 Alzhemed TM 54 Erimos 54 PDX pralatrexate 54 rifalazil 54 Fodosine 54 Neuvenge 54 ENESTnd 54 BrachySil 54 mitogen activated ERK kinase 54 Active Biotech NASDAQ OMX 54 HuMax CD#b 54 ZACTIMA 54 potent suppressor 54 corticosteroid dexamethasone 54 BAY #-# 54 Stimuvax R 54 Voraxaze 54 TASQ 54 thetreatment 54 inhaled iloprost 54 PREOS 54 human IgG1 monoclonal 54 bosutinib 54 OncoVEX 54 zanolimumab 54 AGHD 54 ISEL 54 siRNAs targeting 54 tesmilifene 54 Catena ® 54 VA# [002] 54 YONDELIS R 54 dextofisopam 54 Tanespimycin 54 IMPACT IMmunotherapy 54 ganetespib 54 Aurora kinase inhibitor 54 noninferiority 54 cytoreductive nephrectomy 54 Kevetrin ™ 54 Iloperidone 54 Trovax 54 Nuvion 54 alagebrium 54 Myocet 54 azilsartan medoxomil 54 PSN# [001] 54 EVIZON TM 54 LymphoStat B TM 54 Neuradiab 54 Nanobody 54 MYDICAR 54 PD2i ® 54 imetelstat GRN#L 54 Phase IIb dose 54 initiated Phase Ib 54 Onalta ™ 54 neuroprotective effects 54 evaluating satraplatin 54 Carfilzomib 54 tasimelteon 54 PF # [001] 54 Enhanze Technology 54 LungSign TM 54 EchoCRT 54 Acapodene 54 L BLP# 54 Lixivaptan 54 Elvitegravir 54 Pagoclone 54 vitro dissolution 54 P2V TM 54 pafuramidine 54 NATRECOR R 54 MyVax personalized immunotherapy 54 ixabepilone 54 AEGR 54 HuMax CD4 54 cancer immunotherapies 54 topical formulation 54 ONTARGET 54 recombinant PSMA vaccine 54 Ophena TM 54 H#N# VLP vaccine 54 Vaxfectin ® 54 PDE inhibitor 54 #beta estradiol 54 clevidipine 54 candidates Dyloject TM 54 Phase III TRIST 54 tramiprosate ALZHEMED TM 54 Bioral Amphotericin B 54 Anticalin R 54 LEAPS TM 54 omega interferon 54 Activity Assay 54 initiate Phase IIb 54 tolerated dose MTD 54 Ocrelizumab 54 Cloretazine R 54 biomarker assays 54 Dextofisopam 54 product ColonSentry TM 53 recurrent malignant glioma 53 prognostic indicators 53 blinded randomized controlled 53 NEUGENE antisense 53 molecular imaging radiopharmaceuticals 53 SIMPADICO 53 florbetaben 53 ChronVac C R 53 figitumumab 53 treatment naive genotype 53 Tesmilifene 53 ICON7 53 DITPA 53 eliglustat tartrate 53 Allovectin 7 53 Pazopanib 53 oral talactoferrin 53 glucokinase activator 53 fibrotic disease 53 receptor tyrosine kinase inhibitor 53 evaluating Actimmune 53 ICA # 53 multicenter prospective 53 Ostarine 53 CURE AF 53 erlotinib Tarceva ® 53 Trastuzumab DM1 53 prospective multicenter randomized 53 Zolinza 53 ABSORB trial 53 ENDEAVOR III 53 Amrubicin 53 Septin9 53 EVIZON 53 AZILECT R 53 Insegia 53 viral kinetic 53 NPC 1C 53 lintuzumab SGN 53 TKB# 53 ENDEAVOR IV 53 ATL/TV# 53 XP #L 53 vismodegib 53 genotoxicity studies 53 Confirmatory 53 ADME properties 53 ZYBRESTAT TM 53 Zenvia Phase III 53 refractory CLL 53 QTinno ™ 53 immunomodulatory therapy 53 ABL inhibitor 53 Solorel ® 53 BioMatrix TM 53 immatics 53 dacetuzumab 53 Vaxfectin R 53 HIV coinfected 53 RRMS patients 53 AP# [003] 53 teduglutide 53 IAP inhibitor 53 generation proteasome inhibitor 53 LabCorp conducts clinical 53 Cinquil 53 APOPTONE 53 Edwards SAPIEN valve 53 NSABP B 53 Pyridorin 53 MAA submission 53 MDV# 53 drug GAP #B# 53 STX# 53 ThGRF 53 oral taxane 53 ACTIVE W 53 Huntexil 53 adipiplon 53 VESTASYNC 53 LEP ETU 53 TriGrid 53 oral treprostinil 53 RE LY ® 53 AZD# 53 Blinatumomab 53 KNS # 53 Toraymyxin TM 53 Genz # 53 ALK inhibitors 53 GED aPC 53 preclinical 53 miglustat 53 PNP inhibitor 53 GeneICE 53 alemtuzumab Campath 53 SYN# 53 APPRAISE 53 candidate DXL# CD# 53 ATTRACT 53 Onko Sure ™ 53 CALGB # [002] 53 BioNumerik 53 randomized multicenter 53 Soliris TM eculizumab